NEW YORK ( TheStreet) -- CHANGE IN RATINGS Bridgepoint ( BPI) downgraded at Deutsche from Hold to Sell. $13 price target. Competitors are cutting prices, which could weigh on earnings. Calpine ( CPN) Downgraded at Jefferies to Hold From Buy. Limited pricing upside in Texas. $21 price target. Gap ( GPS) downgraded at Goldman from Buy to Neutral. $40 price target. Company could face near-term sales and margin headwinds. GrafTech ( GTI) upgraded at Jefferies to Buy from Hold, Jefferies said. $12 price target. Pricing prospects for graphite electrodes has improved, combined with significant cost reductions. KSS) upgraded at UBS to Buy from Neutral, according to UBS. $69 price target. Turnaround strategy focused on EBIT growth in place, along with slight operating improvement. Omnicom ( OMC) upgraded at BMO to Outperform. $77 price target. Publicis merger should go through and the company is likely to buy back a lot of shares. Occidental Petroleum ( OXY) upgraded at Barclays to Overweight from Equal Weight. $108 price target. Shares have lagged and restructuring announcements coming. Range Resources ( RRC) downgraded at Barclays to Underweight from Neutral. $71 price target. Results lag peers despite premier acreage. Republic Services ( RSG) downgraded at Wedbush from Outperform to Neutral. $35 price target. Industry pricing outlook is weak. Boston Beer ( SAM) upgraded at Williams from Perform to Outperform. $263 price target. Company is seeing higher revenue growth. Teva Pharmaceuticals ( TEVA) downgraded at JP Morgan to Underweight from Neutral. $38 price target. Too much uncertainty following CEO departure. Time Warner Cable ( TWC) upgraded at Deutsche NOV 04, 2013 | 7:44 AM EST TWC was upgraded from Hold to Buy, Deutsche Bank said. $141 price target. Company fundamentals appear to be bottoming.
Mohawk ( MHK) estimates, target raised at Credit Suisse. Shares of MHK now seen reaching $142, according to Credit Suisse. Estimates also increased, as the company is cutting costs. Neutral rating. Prestige Brand Holdings ( PBH) lowers its estimates, price target at Jefferies. Worsening Nielsen trends and competitive risk will extend into next year. $30 price target and Hold rating. West Pharmaceutical ( WST) increases estimates, price target at Jefferies. WST bumped up its estimates across the board, Jefferies said. Higher sustainable growth and margin in Packaging. $45 price target and Hold rating.